Antifungal drug discovery and development company announces the completion of a $30 million equity financing round

Final Fund Size of £101.3 Million ($158 Million)

Matthew Goodman from the Sunday Times explores the growth in electronic cigarettes

MANCHESTER, UK, May 30, 2012 – CN Creative, Ltd. (CNC), a healthcare company providing innovative and sustainable solutions to reduce smoking and smoking-related illnesses, today reported advances in the company’s regulatory and market initiatives for its Nicadex™ electronic inhaler nicotine replacement therapy (NRT) product and Intellicig® electronic cigarettes.

4-Antibody and Evotec launch a new high-content screening platform for early antibody functionality testing

Jazz Pharmaceuticals Enters Definitive Agreement to Acquire EUSA Pharma
for $650 million in cash plus a potential $50 million milestone payment

CN Creative, Ltd. (CNC), a healthcare company providing innovative and sustainable solutions to reduce smoking and smoking-related illnesses, today announced that Tim Byrne has been appointed Chief Financial Officer.